Patent classifications
A61K38/1808
METHODS AND COMPOSITIONS FOR USE OF GROWTH FACTOR ANTIBODIES IN COMBINATION WITH NON-TYROSINE TARGETING KINASE INHIBITORS
The disclosure relates to methods for treating cancer. More particularly, the disclosure relates to use of chimeric non-natural synthetic proteins, in combination with non-tyrosine targeting kinase inhibitors (NTKIs), in treating cancer and preventing intrinsic and/or acquired resistance to NTKIs.
Vesicles comprising epidermal growth factor and compositions thereof
The invention relates to vesicles comprising Epidermal Growth Factor (EGF), a cationic surfactant and cholesterol or derivatives thereof. The invention also discloses a procedure for their preparation, based on compressed fluid technology (CFs). The vesicles of the invention are useful in the manufacture of drugs and cosmetics and in tissue engineering.
STABILIZED COLOSTRUM COMPOSITIONS
Compositions are provided comprising a pro-reparative factor such as a colostrum, a nutritional protease inhibitor to decrease enzymatic digestion of the pro-reparative factors, and optionally a stabilizing agent, to allow the pro-reparative factors to reach the small intestine intact following oral administration. Methods are provided for treating, alleviating, and preventing inflammatory bowel disease (IBD) and other disorders of the gastrointestinal tract.
NANOFIBER- AND NANOWHISKER-BASED TRANSFECTION PLATFORMS
Described herein are electrospun core-shell fibers that include (i) a central core that is electrically conductive having an exterior surface, wherein the core comprises a first polymer and an electroconductive material; (ii) a shell adjacent to the exterior surface of the core, the shell comprising a second polymer; and (iii) one or more bioactive agents in the shell. In one aspect, the fibers are electrospun fibers. Additionally, described herein are methods for making and using the core-shell fibers.
Freeze-Dried Preparations Comprising Megakaryocytes and Platelets
The problem that differences among lots in components and amounts of growth factors and the like in platelet-rich plasmas derived from an autologous plasma and the freeze-dried preparations thereof are large, and the effects of the lots are not kept constant is solved.
Specifically, a freeze-dried preparation comprising megakaryocytes and platelets induced to differentiate from stem cells, a pharmaceutical composition comprising the freeze-dried preparation, and the like are provided.
Pharmaceutical or cosmetic composition for preventing or treating hair loss or promoting hair growth
A pharmaceutical composition or a cosmetic composition for treating hair loss, or promoting hair growth is described. The composition according to the present invention exhibits an excellent effect of treating hair loss and promoting hair growth, and can be safely used regardless of sex and age.
COMPOSITIONS FOR TREATMENT OF INFERTILITY CAUSED BY POOR SEMEN QUALITY, METHODS FOR PREPARING THE SAME AND APPLICATIONS THEREOF
The present disclosure generally relates to the field of infertility, and in particular male infertility. Accordingly, the present disclosure provides for compositions and methods for managing male infertility, caused by poor semen quality. More particularly, the present disclosure provides a therapeutic composition comprising a platelet rich plasma (PRP) or a growth factor concentrate derived therefrom and a thermoresponsive polymer. The present disclosure also relates to the compositions of PRP and the concentrate themselves. Consequently, methods to obtain the said compositions, along with therapeutic applications for treatment of infertility caused by poor semen quality are also provided.
REGENERATIVE BIOACTIVE SUSPENSION DERIVED FROM FRESHLY DISAGGREGATED TISSUE AND METHODS OF USE IN CLINICAL THERAPIES
A bioactive suspension derived from freshly disaggregated tissue is provided, as well as related methods of formulation and use. The bioactive suspension may comprise a cell-free supernate derived from epidermal and dermal tissue that has been enzymatically and mechanically disaggregated, then separated, and which may contain tissue regeneration factors known to speed healing. The bioactive suspension may further comprise genetically-modified treatment cells, wild type cells, or both, and may be combined with one or more scaffolding elements to form a bioactive suspension combination product suitable for treatment of a cutaneous defect. Synthetic bioactive suspensions and bioactive suspension combination products are also provided.
SKIN COMPOSITION
The present invention pertains to: the provision of a method for promoting skin wound healing and a composition to be used for promoting skin wound healing; the provision of a method useful for preventing or ameliorating ulcers and bedsores or a composition therefor; the provision of a method for preventing skin aging and a composition to be used for preventing skin aging; the provision of a composition useful for preventing or ameliorating skin damage caused by an anticancer agent; and, furthermore, the provision of a method for enhancing the regeneration ability of epidermal stem cells and a composition for enhancing the regeneration ability of epidermal stem cells. More specifically, use of a composition, said composition being characterized by comprising, as an active ingredient, a substance selected from the group consisting of a substance which induces or maintains the expression of COL17A1 in cells, a substance which inhibits the degradation of COL17A1 in cells, a substance which promotes the competitive amplification ability of epidermal stem cells, a substance which suppresses genomic stress or oxidative stress in cells and a substance which prevents DNA damage in cells, enables the promotion of skin wound healing, protection from an anticancer agent and prevention of skin aging. Thus, the regeneration ability of epidermal stem cells can be enhanced.
IDENTIFICATION OF AN EGFR-BIN3 PATHWAY THAT ACTIVELY SUPPRESSES INVASION AND REDUCES TUMOR SIZE IN GLIOBLASTOMA
The present disclosure is concerned with the use of agents that modulate bridging integrator 3 (BIN3) signaling and/or janus kinase 3 (JAK3) signaling for treating various gliomas such as, for example, glioblastoma. The present disclosure is also concerned with the use of agents that increase levels of EGFR ligand (e.g., tofacitinib, EGFR ligands) for treating gliomas, and, in particular, for treating EGFR amplified gliomas. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.